A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
Double-blind, Partially Randomized, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of 100 mg and 150 mg Monthly Oral Ibandronate in Women With Postmenopausal Osteoporosis Having Completed the Phase III Oral Ibandronate Trial BM16549
Sponsor: Hoffmann-La Roche
Listed as NCT00081653, this PHASE4 trial focuses on Post-Menopausal Osteoporosis and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 8 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Feb 2017 — Aug 2017 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
May 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Balatonfüred, Hungary , Ballerup Municipality, Denmark , Barcelona, Spain , Berlin, Germany , Budapest, Hungary , Hanover, Germany , Haugesund, Norway , Kiskunhalas, Hungary , Krakow, Poland and 20 more locations